Physician profile
Rupa Goolsby
NPI 1104843192
$3,092.85
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $251 · 2021: $363 · 2022: $678 · 2023: $756 · 2024: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,139 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.65 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $490.82 | 2019-2023 | |
| Astellas Pharma US INC | $376.41 | 2019-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $368.33 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $248.56 | 2023-2024 | Gemtesa, Myfembree |
| Medtronic, INC. | $197.61 | 2022-2024 | Ligasure |
| Mayne Pharma Commercial LLC | $194.26 | 2021-2023 | |
| Therapeuticsmd, INC. | $163.36 | 2019-2022 | |
| Amgen INC. | $160.10 | 2019-2024 | Evenity, Prolia |
| Urovant Sciences INC | $92.13 | 2021-2022 | |
| Evofem Biosciences, INC. | $84.59 | 2021-2022 | |
| Boston Scientific Corporation | $73.54 | 2019-2024 | Advantage System |
| Millicent US INC | $68.32 | 2023-2024 | Intrarosa, Femring |
| Shield Therapeutics INC | $61.45 | 2023-2024 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $60.36 | 2019-2023 | |
| Mission Pharmacal Company | $55.19 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $48.53 | 2019-2021 | |
| Hologic Sales and Service, LLC | $40.98 | 2019-2020 | |
| Exeltis, USA INC. | $31.17 | 2023-2024 | Slynd |
| Myovant Sciences INC. | $26.51 | 2021-2022 | |
| Intuitive Surgical, INC. | $26.39 | 2019 | |
| Amag Pharmaceuticals, INC. | $25.51 | 2019-2020 | |
| Minerva Surgical, INC | $21.59 | 2023 | |
| Roche Diagnostics Corporation | $20.11 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.55 | 2022 | |
| Radius Health, INC. | $19.35 | 2019 | |
| Axonics, INC. | $18.61 | 2022 | |
| Exact Sciences Corporation | $17.44 | 2023 | Cologuard Collection Kit |
| Ethicon US, LLC | $16.17 | 2020 | |
| Merck Sharp & Dohme LLC | $13.69 | 2019 | |
| Avion Pharmaceuticals | $13.43 | 2023 | Balcoltra |
| Duchesnay USA Incorporated | $13.25 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.90 | 2023 | Seglentis |
| Mylan Pharmaceuticals INC. | $12.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupa Goolsby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.